CURRENT OPINION IN ONCOLOGY

Immunotherapy in patients with early stage resectable nonsmall cell lung cancer

Targeting the androgen receptor and overcoming resistance in prostate cancer

Molecular genetics of head and neck squamous cell carcinoma

Chordoma: update on disease, epidemiology, biology and medical therapies

Adjuvant treatment for endometrial cancer.

Adrenal tumours: open surgery versus minimally invasive surgery.

Use of noninvasive imaging in the management of skin cancer.

Targeting the interplay between metabolism and epigenetics in cancer

Computational analysis of flow cytometry data in hematological malignancies: future clinical practice?

p53, stem cell biology and childhood blastomas

The microenvironment in myeloma.

Diffuse intrinsic pontine glioma: molecular landscape and emerging therapeutic targets.

Malignant pheochromocytoma and paraganglioma: management options.

T-cell receptor and chimeric antigen receptor in solid cancers: current landscape, preclinical data and insight into future developments.

Beyond tissue biopsy: a diagnostic framework to address tumor heterogeneity in lung cancer.

The tumor microenvironment in renal cell cancer

PET imaging in renal cancer

Neurological malignancies in neurofibromatosis type 1.

Impact of ovarian function suppression in premenopausal women with estrogen receptor-positive early breast cancer

Immunotherapy in nonmuscle invasive bladder cancer: current and emerging treatments

Checkpoints inhibitors in the (neo)adjuvant setting of solid tumors: lessons learnt and perspectives.

Angiogenesis inhibition in non-small cell lung cancer: a critical appraisal, basic concepts and updates from American Society for Clinical Oncology 2019.

Window of Opportunity trials for biomarker discovery in breast cancer.

Single-cell sequencing in hematology.

Novel molecular targets for the treatment of lung cancer.

New perspectives in Merkel cell carcinoma

The emergence of long-term survivors in recurrent and metastatic squamous cell head and neck cancer

Advanced cutaneous squamous cell carcinoma: how is it defined and what new therapeutic approaches are available?

Management of leptomeningeal carcinomatosis and challenges of trial design.

Chemotherapy remains a cornerstone in the treatment of nonsmall cell lung cancer.

Circulating biomarkers for the detection of tumor recurrence in the postsurgical follow-up of differentiated thyroid carcinoma.

Immunotherapy of heterogenous sarcomas: questions and strategies.

Current role of poly(ADP-ribose) polymerase inhibitors: which poly(ADP-ribose) polymerase inhibitor and when?

Targeted therapies in melanoma beyond BRAF: targeting NRAS-mutated and KIT-mutated melanoma.

Follicular lymphomas in vulnerable/older patients.

Molecular prediction of metastasis in cutaneous squamous cell carcinoma.

Targeting BRAF and MEK inhibitors in melanoma in the metastatic, neoadjuvant and adjuvant setting.

Update on transarterial approaches to locoregional treatment in hepatocellular carcinoma.

Approaches for vulnerable and frail older patients with diffuse large B-cell lymphomas.

Mantle cell lymphoma in patients not eligible for autologous stem cell transplantation.

Integrated treatment of brain metastases.

Multicultural approaches of cancer pain.

How to assimilate the tsunami of immune checkpoints inhibitors data into clinical practice?

Thymic malignancies: emerging systemic therapies.

Harmonizing gene signatures to predict benefit from adjuvant chemotherapy in early breast cancer.

Palliative care in glioma management.

Role of dose-dense chemotherapy in high-risk early breast cancer.